Clinical Characteristics of Patients Requiring a Second Dose of Radioactive Iodine for the Treatment of Graves’ Disease | oneGRAVESvoice
Global Search
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Abstracts & Posters

Clinical Characteristics of Patients Requiring a Second Dose of Radioactive Iodine for the Treatment of Graves’ Disease

key information

source: Thyroid

year: 2018

authors: O’Keeffe DT, Abdullah A, Bell M

summary/abstract:

Graves’ disease is an autoimmune condition affecting the thyroid gland and is a common cause of hyperthyroidism. The main treatment goals are the reduction in thyroid hormone overproduction either with antithyroid drugs (ATD), surgery or radioactive iodine (RAI) therapy.

The aim of RAI (I-131) therapy is to treat hyperthyroidism by destroying sufficient thyroid tissue to render the patient either euthyroid or hypothyroid. The objective of this work was to examine the outcomes of RAI treatment for Graves’ disease in a large patient cohort over a two year period in a West of Ireland tertiary referral academic medical centre.

In particular, we focused on the characteristics of those patients requiring a second RAI administration. Institutional Review Board approval was obtained for this study and thereafter the clinical records of all the patients who underwent RAI treatment were examined. The data demonstrated that 150 patients underwent RAI treatment from Jan 2014 to Dec 2015.

organization: University Hospital Galway, Ireland

DOI: 10.1089/thy.2018.29065.abstracts

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Powered by

Brought to you by

Supported through an independent
educational grant by

© 2022 rareLife solutions Inc.